Login
- Dokumenttyp:
- Article; Journal Article
- Autor(en):
- Kraus, Sabrina; Klassen, Philipp; Kircher, Malte; Dierks, Alexander; Habringer, Stefan; Gäble, Alexander; Kortüm, Klaus Martin; Weinhold, Niels; Ademaj-Kospiri, Valëza; Werner, Rudolf A; Schirbel, Andreas; Buck, Andreas K; Herhaus, Peter; Wester, Hans-Jürgen; Rosenwald, Andreas; Weber, Wolfgang A; Einsele, Hermann; Keller, Ulrich; Rasche, Leo; Lapa, Constantin
- Titel:
- Reduced splenic uptake on 68Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis.
- Abstract:
- Beyond being a key factor for tumor growth and metastasis in human cancer, C-X-C motif chemokine receptor 4 (CXCR4) is also highly expressed by a number of immune cells, allowing for non-invasive read-out of inflammatory activity. With two recent studies reporting on prognostic implications of the spleen signal in diffusion-weighted magnetic resonance imaging in patients with plasma cell dyscrasias, the aim of this study was to correlate splenic 68Ga-Pentixafor uptake in multiple myeloma (MM) with clinical parameters and to evaluate its prognostic impact. Methods: Eighty-seven MM patients underwent molecular imaging with 68Ga-Pentixafor-PET/CT. Splenic CXCR4 expression was semi-quantitatively assessed by peak standardized uptake values (SUVpeak) and corresponding spleen-to-bloodpool ratios (TBR) and correlated with clinical and prognostic features as well as survival parameters. Results:68Ga-Pentixafor-PET/CT was visually positive in all MM patients with markedly heterogeneous tracer uptake in the spleen. CXCR4 expression determined by 68Ga-Pentixafor-PET/CT corresponded with advanced disease and was inversely associated with the number of previous treatment lines as compared to controls or untreated smouldering multiple myeloma patients (SUVpeakSpleen 4.06 ± 1.43 vs. 6.02 ± 1.16 vs. 7.33 ± 1.40; P < 0.001). Moreover, reduced splenic 68Ga-Pentixafor uptake was linked to unfavorable clinical outcome. Patients with a low SUVpeakSpleen (<3.35) experienced a significantly shorter overall survival of 5 months as compared to 62 months in patients with a high SUVpeakSpleen >5.79 (P < 0.001). Multivariate Cox analysis confirmed SUVpeakSpleen as an independent predictor of survival (HR 0.75; P = 0.009). Conclusion: These data suggest that splenic 68Ga-Pentixafor uptake might provide prognostic information in pre-treated MM patients similar to what was reported for diffusion-weighted magnetic resonance imaging. Further research to elucidate the underlying biologic implications is warranted.
- Zeitschriftentitel:
- Theranostics
- Jahr:
- 2022
- Band / Volume:
- 12
- Heft / Issue:
- 13
- Seitenangaben Beitrag:
- 5986-5994
- Volltext / DOI:
- doi:10.7150/thno.75847
- PubMed:
- http://view.ncbi.nlm.nih.gov/pubmed/35966583
- TUM Einrichtung:
- Klinik und Poliklinik für Nuklearmedizin
BibTeX